| Dr Syed M Yunus Raza Naqvi, MD | |
|
164 Summit Ave, Providence, RI 02906-2853 | |
| (401) 793-4489 | |
| Not Available |
| Full Name | Dr Syed M Yunus Raza Naqvi |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 10 Years |
| Location | 164 Summit Ave, Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235651332 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | MD16963 (Rhode Island) | Secondary |
| 390200000X | Student In An Organized Health Care Education/training Program | 272004 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Miriam Hospital | Providence, RI | Hospital |
| Rhode Island Hospital | Providence, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lifespan Physician Group Inc | 2567455082 | 631 |
News Archive
Bacterin International, Inc., a developer of revolutionary bone graft material, today announced a three-year agreement to provide its biologic line of products, OsteoSponge®, OsteoSelect®, OsteoSponge SC®, OsteoWrap®, BacFast®, and OsteoLock®, to the vast Broadlane® nationwide network of hospitals and medical practices.
Hospital participation in the National Voluntary Hospital Reporting Initiative is booming as the Centers for Medicare & Medicaid Services (CMA) posts its second web site refresh of hospital quality of care data, CMS Administrator Mark B. McClellan, M.D., Ph.D., announced today.
Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd., today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Atorvastatin and has launched the product in the U.S. market.
A third of patients with advanced or metastatic melanoma will achieve an objective response to treatment with the programmed cell death protein inhibitor pembrolizumab, suggest KEYNOTE-001 findings, regardless of whether they have previously been treated with ipilimumab.
› Verified 7 days ago
| Entity Name | Lifespan Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407116643 PECOS PAC ID: 2567455082 Enrollment ID: O20121029000368 |
News Archive
Bacterin International, Inc., a developer of revolutionary bone graft material, today announced a three-year agreement to provide its biologic line of products, OsteoSponge®, OsteoSelect®, OsteoSponge SC®, OsteoWrap®, BacFast®, and OsteoLock®, to the vast Broadlane® nationwide network of hospitals and medical practices.
Hospital participation in the National Voluntary Hospital Reporting Initiative is booming as the Centers for Medicare & Medicaid Services (CMA) posts its second web site refresh of hospital quality of care data, CMS Administrator Mark B. McClellan, M.D., Ph.D., announced today.
Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd., today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Atorvastatin and has launched the product in the U.S. market.
A third of patients with advanced or metastatic melanoma will achieve an objective response to treatment with the programmed cell death protein inhibitor pembrolizumab, suggest KEYNOTE-001 findings, regardless of whether they have previously been treated with ipilimumab.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Syed M Yunus Raza Naqvi, MD 117 Ellenfiled Street, Suite 101, Providence, RI 02905 Ph: (401) 444-6779 | Dr Syed M Yunus Raza Naqvi, MD 164 Summit Ave, Providence, RI 02906-2853 Ph: (401) 793-4489 |
News Archive
Bacterin International, Inc., a developer of revolutionary bone graft material, today announced a three-year agreement to provide its biologic line of products, OsteoSponge®, OsteoSelect®, OsteoSponge SC®, OsteoWrap®, BacFast®, and OsteoLock®, to the vast Broadlane® nationwide network of hospitals and medical practices.
Hospital participation in the National Voluntary Hospital Reporting Initiative is booming as the Centers for Medicare & Medicaid Services (CMA) posts its second web site refresh of hospital quality of care data, CMS Administrator Mark B. McClellan, M.D., Ph.D., announced today.
Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd., today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Atorvastatin and has launched the product in the U.S. market.
A third of patients with advanced or metastatic melanoma will achieve an objective response to treatment with the programmed cell death protein inhibitor pembrolizumab, suggest KEYNOTE-001 findings, regardless of whether they have previously been treated with ipilimumab.
› Verified 7 days ago